CN102318835B - Composition for reducing bone loss and preparation method thereof - Google Patents
Composition for reducing bone loss and preparation method thereof Download PDFInfo
- Publication number
- CN102318835B CN102318835B CN 201110255107 CN201110255107A CN102318835B CN 102318835 B CN102318835 B CN 102318835B CN 201110255107 CN201110255107 CN 201110255107 CN 201110255107 A CN201110255107 A CN 201110255107A CN 102318835 B CN102318835 B CN 102318835B
- Authority
- CN
- China
- Prior art keywords
- calcium
- vitamin
- powder
- bone
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 206010065687 Bone loss Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 61
- 102000008186 Collagen Human genes 0.000 claims abstract description 38
- 108010035532 Collagen Proteins 0.000 claims abstract description 38
- 229920001436 collagen Polymers 0.000 claims abstract description 38
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 28
- 239000011772 phylloquinone Substances 0.000 claims abstract description 25
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 23
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 21
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 16
- 229940043430 calcium compound Drugs 0.000 claims abstract description 16
- 150000001674 calcium compounds Chemical class 0.000 claims abstract description 16
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 16
- 239000011718 vitamin C Substances 0.000 claims abstract description 16
- 230000001965 increasing effect Effects 0.000 claims abstract description 7
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 4
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 60
- 239000011575 calcium Substances 0.000 claims description 60
- 229960005069 calcium Drugs 0.000 claims description 60
- 229910052791 calcium Inorganic materials 0.000 claims description 60
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 claims description 27
- 229930003316 Vitamin D Natural products 0.000 claims description 27
- 235000019166 vitamin D Nutrition 0.000 claims description 27
- 239000011710 vitamin D Substances 0.000 claims description 27
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 27
- 229940046008 vitamin d Drugs 0.000 claims description 27
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 25
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims description 25
- 239000011248 coating agent Substances 0.000 claims description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 235000013402 health food Nutrition 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 11
- 210000002784 stomach Anatomy 0.000 claims description 11
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 10
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 10
- 239000007888 film coating Substances 0.000 claims description 10
- 238000009501 film coating Methods 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000007884 disintegrant Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 229960001714 calcium phosphate Drugs 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- 241000143437 Aciculosporium take Species 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- 108010033929 calcium caseinate Proteins 0.000 claims description 2
- 229940092124 calcium citrate malate Drugs 0.000 claims description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920003081 Povidone K 30 Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 75
- 238000012360 testing method Methods 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 35
- 230000037182 bone density Effects 0.000 abstract description 28
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract description 9
- 229930003427 Vitamin E Natural products 0.000 abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 7
- 235000019165 vitamin E Nutrition 0.000 abstract description 7
- 229940046009 vitamin E Drugs 0.000 abstract description 7
- 239000011709 vitamin E Substances 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 abstract 1
- 108010001441 Phosphopeptides Proteins 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 239000005018 casein Substances 0.000 abstract 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
- 235000021240 caseins Nutrition 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 235000019175 phylloquinone Nutrition 0.000 abstract 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 abstract 1
- 229960001898 phytomenadione Drugs 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 25
- 208000001132 Osteoporosis Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 12
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 239000011782 vitamin Substances 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 230000037118 bone strength Effects 0.000 description 10
- 230000001934 delay Effects 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- 229930003448 Vitamin K Natural products 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000011712 vitamin K Substances 0.000 description 8
- 235000019168 vitamin K Nutrition 0.000 description 8
- 150000003721 vitamin K derivatives Chemical class 0.000 description 8
- 229940046010 vitamin k Drugs 0.000 description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229960002442 glucosamine Drugs 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- -1 ammonia carbohydrate Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000008924 Femoral Fractures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010041611 Spine malformation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000011001 calcium citrates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for reducing bone loss and a preparation method thereof. The composition is prepared from a calcium compound, marine fishbone collagen oligopeptide powder, glucosamine hydrochloride, casein phosphopeptides, natural vitamin E, vitamin C, vitamin K1, vitamin B12, vitamin D3 and dietary fiber. As proved by animal and human body tests, the composition has the effects of increasing bone density, enhancing bone intensity, reducing bone loss, delaying aging and enhancing the immunity, and can be taken by the middle-aged and old as a health-care food for a long time. The preparation method is scientific and reasonable, and is suitable for industrial production.
Description
Technical field
The present invention relates to a kind of composition and method of making the same that reduces bone-loss, is a kind of health food that can strengthen bone density, increase bone toughness and elasticity, the aging of prevention bone specifically, belongs to food technology field.
Background technology
Aging is body tissue structural change and the hypokinetic a kind of organic growth process that occurs along with the increase at age.Be accompanied by human senility, the metabolism of body bone also can get muddled, balance between Gegenbaur's cell and osteoclast effect is broken, bone absorbs greater than bone and forms, and causes that the bone amount reduces, and bone density descends, finally cause osteoporosis, pain in back and loin, spine malformation can be arranged, and very easily fracture, have a strong impact on people's quality of life.In addition, the osteoporosis that deteriorates to feature with low bone amount and bone tissue fine structure becomes middle-aged and old common disease and frequently-occurring disease, and it is the systemic disease that causes the increase of bone fragility and Decrease of Bone Mineral Density and fracture risk to increase.According to statistics, the women's osteoporosis incidence of disease more than 60 years old is 60-70%, and performance has osteoporotic middle-aging male that certain proportion is also arranged.The clinical manifestation of osteoporosis mainly is that whole body ostalgia is unable, and take the small of the back and fracture site rest pain as main, activity obviously is restricted.Along with the continuous growth of population and the arrival of astogeny society, its incidence is gradually ascendant trend, gradually, become a serious social concern, therefore many people suffer sensual misery for a long time, even wounded or disabled and early death, high medical fee brings heavy financial burden and huge stress also for family and society.The control of osteoporosis has become one of global important public hygiene problem at present, has become the serious hot issue of paying close attention to of society.About 200,000,000 people in the whole world suffer from osteoporosis, and its incidence of disease has leapt to common disease, frequently-occurring disease the 7th.The osteoporotic Chinese and Western medicine for the treatment of is more at present, but the complex treatment effect is very unobvious mostly, and rehabilitative action is also significantly little, has the imperfection part, is up to the present medically not yet finding safe and effective radical cure method.
Bone density, full name " bone mineral density " is the leading indicator of bone strength, is an important symbol of bone mass, reflection osteoporosis degree, the important evidence of prediction fracture risk.People's bone density is will be with the growth at age year by year because bone loss descends behind the peaking about 30 years old, and the speed of women's bone loss after climacteric begins is faster than elderly men.It is reported, men and women no matter, after 60 years old, 20%～30% during the general peaking of bone loss amount, maximum reaches 40%.With advancing age, compare with the young man below 30 years old under the identical nutritional condition, these the elderly sclerotin still occurs inevitably and lose in a large number, bone density descends, bone strength reduces, become gradually loose easy to break, thereby the elderly often causes osteoporosis that fracture without inducement occurs because bone density descends, especially good position is femur and lumbar vertebrae.
Therefore, more and more pay attention to today of life quality and living space people, how to strengthen the body ability that delays senility, increase bone density and intensity, help loose bone to restore to the original state, it is particularly important that the delaying human body caducity process seems, and have positive realistic meaning.Therefore exploitation increase bone density is very necessary with the health food that delays senility.
A Chinese patent, CN101695382 A number disclose a kind of calcium-supplementing preparation that improves bone and function of joint that has concurrently, chief component is calcium source, ammonia carbohydrate, CPP, bone collagen, anti-oxidant composition etc., its preparation technology becomes fine powder with each raw material mixed grinding, excessively compressing tablet behind the 60-150 mesh sieve.But there is not vitamin D in this patented foodstuff composition; Simultaneously, although it contains bone collagen, do not consider that can bone collagen be absorbed by the body, in addition, among its preparation technology raw material is directly mixed abrasive dust, its flowability and poor compressibility, can't realize suitability for industrialized production, product weight difference is large, affects product quality.
Summary of the invention
The present invention seeks to overcome above-mentioned prior art defective, a kind of composition that reduces bone-loss is provided, it can consider the influence factor that stops the old and feeble health food links of bone, component is reasonable, health-care effect is obvious, is suitable for suitability for industrialized production.
Simultaneously, the present invention also will provide the preparation method of this health food.
Purpose of the present invention is achieved through the following technical solutions.
A kind of composition that reduces bone-loss, it is made by the component of following weight portion:
Calcium compound 30-80 part, the oligomeric Gly-His-Lys 1-50 of Marine fishbone collagen part, aminoglucose hydrochloride 5-30 part, CPP 1-20 part, natural VE powder 0.25-7.5 part, vitamin C 1.5-50 part, vitamin K
1Powder 0.02-0.1 part, Cobastab
120.00005-0.0005 part, vitamin D
3Powder 0.000075-0.0005 part, dietary fiber 1-20 part.
The composition of above-mentioned minimizing bone-loss, its preferred component content is: calcium compound 40-60 part, the oligomeric Gly-His-Lys 5-20 of Marine fishbone collagen part, aminoglucose hydrochloride 8-20 part, CPP 4-10 part, natural VE powder 4-10 part, vitamin C 4-10 part, vitamin K
1Powder 0.02-0.05 part, Cobastab
120.00008-0.0001 part, vitamin D
3Powder 0.00009-0.0002 part, dietary fiber 2-8 part.
Calcium compound is at least a in calcium carbonate, calcium citrate, calcium gluconae, calcium lactate, calcium malate, Calcium Ascorbate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, calcium acetate, calcium caseinate, calcium chloride, calcium citrate malate, calcium phosphate, calcium sulfate, calcium glycerophosphate or the amino acid chelated calcium in the described component.
Ossein refers to that molecular weight is less than the oligomeric Gly-His-Lys of 1000 daltonian Marine fishbone collagens.
The composition of above-mentioned minimizing bone-loss, it also comprises the auxiliary material of following weight portion:
Diluent 0-40 part, disintegrant 0-10 part, lubricant 0.5-5 part, adhesive 0-5 part, coating agent 0-3 part.
The preferred content of described auxiliary material is: diluent 4-10 part, disintegrant 1-5 part, lubricant 0.8-2 part, adhesive 0.5-3 part, coating agent 2-3 part.
The component of food compositions of the present invention and dosage ratio are according to the anti-ageing theory in the modern medicine and medicines and health protection health theory and modern pharmacology Theoretical Design, purpose is the cause of disease that occurs for middle-aged and old osteoporosis of modern times, a kind of function is definite, the long-term taking that has no side effect but provide to people on the root, can stop the health food that bone is old and feeble, reinvent young bone from root.
The present invention prescription is that sorbefacient, multivitamin, aminoglucose hydrochloride, ossein (the oligomeric Gly-His-Lys of Marine fishbone collagen), the dietary fiber take calcium complement agent, calcium is the basis, and having overcome on the market much, products improve the weakness that osteoporosis is replenished the calcium merely for the elderly.Sorbefacient (CPP, the VD of calcium complement agent (calcium source) and calcium
3) and VK
1, VB
12Combination, the bone density that can effectively improve the elderly descends, and improves bone strength; Marine fishbone collagen oligopeptide has replenished the required ossein of bone, has strengthened bone toughness and can prevent calcium loss, and the raw material choice for use molecular weight of ossein easily absorbs less than the oligomeric Gly-His-Lys of 1000 daltonian Marine fishbone collagens, and biological utilisation improves; Aminoglucose hydrochloride has increased joint flexibility ratio and bone toughness; Natural VE, VC can effectively remove free radical, and the specific (special) requirements that satisfied the elderly delays senility has stoped bone old and feeble; Simultaneously, consider use crowd's characteristic, along with the age increases, middle-aged and old gastrointestinal functions also decrease, and activity reduces in addition, easily constipation.The while long-term taking contains calcium product and also causes easily constipation, and middle-aged and old intestines and stomach defaecation problems has been regulated in the suitable adding of dietary fiber.In sum, the present invention has stoped middle-aged and old bone old and feeble from root, can reinvent out younger bone, and safely, have no side effect, can eat for a long time.
Contain vitamin D in the composition of the present invention
3, Cobastab
12, vitamin K
1, by with do not contain vitamin D
3, Cobastab
12, vitamin K
1The blank group relatively, after the volunteer that replenishes the calcium takes 1 month, by dual energy X-ray absorptiometry, measure two groups lumbar vertebrae and femur density, find to contain vitamin D
3, Cobastab
12, vitamin K
1Present composition group can obviously improve the bone tissue mechanical strength (P＜0.01) of bone BMD and lumbar vertebrae and femur, reflected that said composition may be by acting on different histoorgans, many target spots, too many levels, multipath are regulated the bone absorption and bone forms, improve bone metabolism situation, can increase the bone amount, keep the normal configuration of bone, the mechanical property of bone is improved, the adding of three kinds of vitamins has produced collaborative facilitation so that the calcareous absorptivity of composition improves 5%.
The preparation method of health food of the present invention is:
A. take by weighing each component and auxiliary material by prescription, with described vitamin C, aminoglucose hydrochloride, vitamin K
1Powder, vitamin D
3Powder, Cobastab
12Sieve respectively, for subsequent use;
B. adhesive is made into the aqueous solution of mass concentration 8%, and is for subsequent use;
C. calcium compound, aminoglucose hydrochloride add the aqueous solution and make respectively softwood, granulate, and drying, whole grain makes calcium compound particle and aminoglucose hydrochloride particle;
D. with vitamin K
1Powder, Cobastab
12, vitamin D
3Powder and CPP shake at Highefficientpowersifter by the equivalent method of progressively increasing and sieve twice, and sieve number is 80 orders, and mixing makes mixture one;
E. described mixture one is shaken at Highefficientpowersifter with vitamin C, natural VE powder and sieve twice, mixing, sieve number is 40 orders, makes mixture two;
F. prepared calcium compound particle, aminoglucose hydrochloride particle, the oligomeric Gly-His-Lys of Marine fishbone collagen, dietary fiber, diluent, disintegrant, lubricant and described mixture dual-purpose mixer among the step c were always mixed 30 minutes, make the total mixture particle, particle is directly packed the granulation agent, or encapsulatedly make capsule or its compressing tablet in tablet press machine is made label;
G. described coating agent is dissolved in the ethanol, stir and add purified water after 10 minutes, stir and made coating solution in 45 minutes, the concentration of coating agent is 10%(W/W in the described coating solution), the concentration of ethanol is 70%, and label described in the step f is put into the tablet that the seed-coating machine dressing namely makes health food.
Above-mentioned preparation method is with whole granule that namely gets health food of the total mixture particle that makes among the step f.
Above-mentioned preparation method namely gets the total mixture granule filling capsule that makes among the step f capsule of health food.
Vitamin powder after the present invention processes with microcapsule technology is done raw material, has both increased product stability, and trace element can be mixed, and has guaranteed the product content uniformity.Its jolt ramming front volume, tap volume are measured, estimate by projects such as Ka Er coefficient, compressibility coefficient, Hausner Ratio and angles of repose, prove that composition molding of the present invention has had obvious change, unilateral smooth, sheet is heavily stable can be easy to control, hardness and friability have reached the requirement of storage and transportation, have improved product quality.Contrast test and technical Analysis are as follows:
Evaluation criterion: it has been generally acknowledged that angle of repose＜40
0, mobile relatively good.
Measure jolt ramming front volume (V according to the method for USP24＜616＞provide
0) and tap volume (V
f), take by weighing sample 50 grams;
Ka Er coefficient=(V
0-V
f)/V
f
Compressibility coefficient=100(V
0-V
f)/V
0
Hausner?Ratio=V
0/V
f；
The evaluation coefficient (related) of compressibility coefficient and Hausner Ratio:
The present composition and the patent No. are the mobile property of the invention composition of CN101695382 A and compressibility measurement result:
。Technical Analysis: all very poor with material fluidity and compressibility that the preparation method that directly mixes behind the crushing material prepares, preparation preparation difficulty.By the sample of this technique preparation through visual examination, tablet weight variation (according to the correlation technique of two ones of Chinese Pharmacopoeia versions in 2010), hardness (according to the detection method to tablet) and friability (according to the correlation technique of two ones of Chinese Pharmacopoeia versions in 2010), testing result is that outward appearance is coarse, tablet weight variation is large, hardness is little, sheet heavily is difficult to control, can not satisfy industrialized production.And by the sample of present composition technique preparation, bright in appearance, tablet weight variation is little, hardness is suitable, friability meets standard-required.The constant product quality of producing, the indices check all meets the requirements, and is well suited for industrialized production.
Through animal experiment and human trial all proved invention product have the function that increases bone density, delays the bone aging, through toxicological test, do not find the toxic effect of this product and mutagenesis etc.Further specifying it below in conjunction with animal and function test increases bone density, delays the function such as bone aging.
Experiment 1: safety non-toxic test
The present invention confirms safety non-toxic through animal experiment, and result of the test and conclusion are as follows:
(1), acute toxicity test: the acute oral MTD of rat all greater than 15g/kg.bw, is declared the genus non-toxic type.
(2), three genetic toxicity tests such as the test of Salmonella reversion test, bone marrow cell micronucleus and sperm malformation test are negative findings, show without mutagenesis.
(3), had no the ANOMALOUS VARIATIONS of animal health condition, biochemistry, hematological indices and organ-tissue form in 30 days in the feeding trial, prove safety non-toxic of the present invention.
Experiment 2: increase the bone substance density improving function test
The present invention confirms to have the increase bone substance density improving function through animal experiment, and result of the test and conclusion are as follows:
The impact heavy on rat body weight, bone (x ± s)
★, compare P＜0.05 with low calcium control group;
Result of the test shows: the low calcium control group of the right femur bone weight average of three dosage groups and high dose calcium carbonate group obviously increases (P＜0.05), has the effect that increases calcium content of bone.
On the impact of rat bone density and calcium content of bone (x ± s)
★, compare P＜0.05 with low calcium control group;
★ ★, compare P＜0.01 with low calcium control group.
Result of the test shows: the bone density of basic, normal, high three dosage groups is significantly higher than low calcium control group (P＜0.01), the right femur calcium content of three dosage groups and high dose calcium carbonate group all low calcium control group obviously increases (P＜0.05), has the effect that increases bone density.
Experiment 3: collagen oligopeptide powder and vitamin K
1Synergy
Molecular weight is less than the oligomeric Gly-His-Lys of 1000 daltonian bone collagens, with vitamin K
1The associating use by the function assessment experiment to bone, in contrast experiment's data demonstration of small white mouse, aspect increase bone density and bone toughness, replenishes the oligomeric Gly-His-Lys of collagen, with vitamin K simultaneously
1It is better than traditional effect of supplemented calcium to unite use, and result of the test is as follows with judgement:
Impact on the rat femur biomechanical
The animal test results of health food of the present invention shows: compare with model control group, 5 times, 10 times, 20 times three dosage group femur calcium content raises, and 10 times, 20 times two dosage group femur dry weight, femur mid point and distal end density also obviously raise.According to " function of health food is learned assessment process and method of inspection standard " (2003 editions), judge the effect that composition of the present invention has increases bone density and bone toughness.
Above-mentioned check is popular, exactly by to the oligomeric Gly-His-Lys of experimental rats feeding bone collagen and vitamin K composition with carry out control experiment that tradition replenishes the calcium and verify that the oligomeric Gly-His-Lys of bone collagen and vitamin K composition are in the effect that increases aspect bone density and the bone toughness, scientific experiment proves, composition of the present invention has the function that increases bone density and bone toughness, can obviously improve the bone strength of human body, also just prove that the oligomeric Gly-His-Lys of collagen hyalronic albumen and vitamin K composition are better than traditional effect of supplemented calcium simultaneously.
Experiment 4: deferring senility test
The present invention confirms to have deferring senility through animal experiment, and every evaluation criterion shows that deferring senility animal test results of the present invention is positive.
The present invention further confirms to have deferring senility through human trial, and concrete result of the test and conclusion are as follows:
Hematology detection index before and after the test (X ± SD)
。Blood MDA content, SOD activity and GSH-Px activity change situation before and after the test (X ± SD)
Annotate: compare P＜0.05 before and after the * self, compare P＜0.05 between the # group
Test front and back blood lipid peroxide (MDA) content situation: compare MDA content before and after the test of test-meal group and all be lower than test front (P＜0.05); And significantly be lower than control group (P＜0.05).
Blood superoxide dismutase (SOD) activity change situation before and after the test: self compare the SOD activity before and after the control group test without significant difference (P＞0.05); Relatively front with test after the test of test-meal group, active significantly raise (P＜0.05) of SOD.
Blood glutathione peroxidase (GSH-Px) activity change situation before and after the test: self compare the GSH-Px activity before and after the control group test without significant difference (P＞0.05); Relatively front with test after the test of test-meal group, active significantly raise (P＜0.05) of GSH-Px.
Delaying senility function shows through the human feeding trial result: the no abnormality seens such as duration of test experimenter's spirit, diet, sleep, stool and urine, the every safety indexes of health check-up is no abnormality seen also, shows that the present invention has no adverse effects to human body.The rear test-meal group MDA content of test significantly is lower than before the test and significantly is lower than control group; Before blood superoxide dismutase (SOD) activity is significantly higher than test; Before blood glutathione peroxidase (GSH-Px) activity also is significantly higher than test.By evaluation criterion: the present invention has deferring senility.
The suitable the elderly of health food of the present invention, eating method is each 1, every day 2 times.
The present invention has no side effect through the evidence of animal and human's body, and has the function that increases bone density, strengthens bone strength, reduces bone-loss and delay senility, and can be the elderly as the health food long-term taking.
Calcium among the present invention is health chats materialization tissue---the essential minerals of bone and tooth, is the basic nutrition of maintaining bone density, also is an important dietary factors that affects bone density.Will bring out hyperparathyroidism when calcium absorption or calcium incomplete absorption, then cause mobilizing from the bone of bone, discharge more calcium to keep the calcium stable of serum, therefore bone loss occurs.Therefore, the status of calcium in prevention and treatment osteoporosis is very important and irreplaceable.Calcium carbonate is as calcium tonic, is the highest a kind of of calcium content, dissolves in hydrochloric acid in gastric juice, is to use maximum calcium tonics.
Ossein is one of main component of bone tissue, for calcified tissue provides requisite three-dimensional structure and mineral deposit is had inducing action.It can promote the depositions of inanimate matter on bone such as calcium, phosphorus, thereby can play and repair bone tissue, improve the osteoporosis symptom, promote healthy effect.The calcium that human body absorbs is just effectively to be utilized by bone by the link effect of ossein.Ossein also is the important component that forms human muscle, skin, has very great help for the toughness, the harmony of human motion and the elasticity of skin that keep bone.Synthetic self ossein of body need to provide sufficient strong proline.The amino acid ratio of components of ossein is more special, and it is rich in strong proline.With age, quantity and the ability of the synthetic collagen of human body self can slowly can't satisfy daily need, and simple effect of supplemented calcium is not good enough, and not enough because if ossein is replenished, the matrix of bone can not form, and calcium salt then can't deposit; Opposite simple additional collagen, more sufficient even bone matrix forms, but calcium deposition is few, still can not make the bone normal growth.The metabolism of ossein can also promote the metabolism of cell, strengthens the nutrition of cartilage synovial membrane, strengthens bone density, increases toughness and the bone strength of bone, thereby plays anti-ageing, as to promote growth effect.
The U.S., Europe and Japanese a large amount of medical researches show: Glucosamine can help to repair and safeguard cartilage and the growth that can stimulate the cartilage cell.An amount of Glucosamine that replenishes of the elderly can prevent the generation of Osteoarthritis, or improve symptom, and is also useful to shoulder pain and gonalgia due to scapulohumeral periarthritis, fascitis, the cervical spondylopathy.When the treatment osteoporosis, replenish Glucosamine, can also increase eburnation degree, flintiness.In addition, Glucosamine also have delay senility, delay senility, the liver defencive function.Test shows: Glucosamine can strengthen the function of body specific cellular immunity and humoral immunity.If together use with antibiotic, can promote the absorption of antibiotic in blood, reduce side reaction, but the also growth of inhibition cancer cell.With advancing age, the shortage of the Glucosamine in the human body is more and more serious, and articular cartilage is constantly degenerated and worn and torn, and suitably replenishes Glucosamine and seems particularly important.
CPP (hereinafter to be referred as CPP) is a kind of good short calcium factor, is described as " mineral carrier ".Studies show that at present the effect that the short calcium of CPP absorbs is mainly manifested in the following aspects: (1) promotes small intestine to the absorption of calcium.Cereal in people's the diet contains a large amount of phytic acid, the contour phosphorus composition of phytic acid, is combined with calcium under small intestine lower end PH7～8 environment and generates calcium phosphate precipitation.And CPP can suppress the formation of calcium phosphate precipitation, makes free calcium keep higher concentration, promotes the Passive intake of calcium, becomes vitamin D as the another approach of accelerating agent of calcium absorption.(2) promote bone to the utilization of calcium.Zoopery shows that CPP can promote absorption and the utilization of calcium, weakens the again absorption of osteoclast effect and inhibition bone.(3) promote tooth to the utilization of calcium.Think that in the past chewing after the meal cheese can exciting salivary secretion, make acidic materials on the saliva buffering dental plaque of alkalescence to adamantine corrosion, help to prevent the generation of carious tooth.Research in recent years finds, the CPP that contains in the cheese can be with the calcium binding in the food at the carious tooth place, alleviate enamel go mineralize, thereby reach anti-dental caries purpose.
Cobastab
12Osteoblastic function there is direct effect, has research to find Cobastab
12With BGP, alkaline phosphatase correlation is arranged.The You Li of affiliated hospital of Shanghai Communications University etc. are to postmenopausal women's blood Cobastab
12, folic acid water product and bone density correlation carried out Primary Study, finds the elderly woman Cobastab
12Bone loss speed is faster than homovitamin B
12Group, concurrent existing osteoporosis is compared Cobastab with the women that the bone amount reduces with the women of normal bone amount
12Level is lower, and each organizes women's folate level no significant difference.This studies show that Cobastab
12With bone density correlation is arranged.
Vitamin C has important function as a kind of important reducing agent in bone salts metabolism and sclerotin generation.It can promote the generation of bone matrix, increases osteogenesis function; It can increase the deposition of calcium salt, stimulates the formation of cultured cell mineralising tubercle, by the differentiation of osteoclast necessary; Being again the raw material of collagen synthesis simultaneously, participating in the proline hydroxylation with synthetic collagen, is to form the necessary material of collagen.Studies have shown that the generation of collagen is influential to bone strength, the NTx defective is little on the BMD impact, but can cause the obvious reduction of bone strength, and the trend of collagenous fibres also can affect bone strength.In the research that osteoblast is cultivated, the interior alkaline phosphatase activities of cell, cell proliferation and the NTx gene mRNA expression that add the VC group all have increase.Ascorbic physiological function main manifestations is: promote the biosynthesis of ossein, be beneficial to the faster healing of tissue injury mouth; The metabolism of tyrosine and tryptophan prolongs the human body life-span in the promotion amino acid; Improve the utilization of iron, calcium and folic acid; Improve fat and the particularly metabolism of cholesterol of lipoid, the prevention cardiovascular disease; Promote the growth of tooth and bone, prevent that gum is hemorrhage, prevent arthralgia, pain in waist and lower extremities; Strengthen human body to external world anti-stress ability and the immunity of environment.
The level of body vitamin D and bone density, the strong density dependent of muscle, vitamin D are the main adjusting factors that calcium absorbs, and can help absorption of human body calcium, effectively improve human bone mineral density and take in the peak value that calcium can be kept to the long duration bone density.It can fully assist calcium effectively to play a role, and promotes new bone calcification and bone to form, and reduces bone loss, significantly increases the elderly's bone density.Shortage or not enough human body also can cause the Secondary cases parathyroid function to increase to the incomplete absorption 10% of calcium, increase the bone conversion, promote bone loss, cause osteoporosis and fracture.Human body self can synthesize a small amount of vitamin D, and this synthetic conversion capability of the elderly declines to a great extent, and the underfed danger of vitamin D occurs to be increased greatly, affects absorption and the utilization of calcium, and vitamin D is just necessary.
Vitamin K increases the synthetic of Gegenbaur's cell BGP as the dependence vitamin of multiple protein in the bone, that is to say the mineralization that can strengthen bone, to osteoporotic prevention and treatment certain effect will be arranged, and its wide material sources, low price.Vitamin K is the key factor that prevention adult bone strength descends, and is even more important to postclimacteric middle aged and aged women.A large amount of survey datas find that if the vitamin K intake in women's meals is lower, the danger that osteoporosis and femoral fracture occur for they is just larger.Yet the strong bone effect of vitamin K and calcium is also inconsistent, and it can't obviously improve the density of bone, but can help calcium to enter better bone matrix, obviously improves the flexural capacity of bone.
Natural VE is the most representative fat-soluble natural agent that delays senility that is positioned film, has powerful anti-radical action, can the Cell protection film and intracellular nucleic acid avoid free radical and attack, be the most effective one of material that delays senility in the human body.Vitamin E can strengthen the delaying senility function of cell.Because vitamin E itself very easily is oxidized to fertility phenolic group and fertility quinonyl, can protect ambient substance not oxidized, eliminates the free radical that body is had detrimental effect in cell, prevents the formation of lipofuscin.Simultaneously vitamin E can also the diaphragm phospholipid composition in unsaturation aliphatic acid, the stabilate membrane structure, diaphragm is kept biomembranous normal function in conjunction with enzyme activity and acceptor etc.
Vitamin C is the same with vitamin E also to be the agent that delays senility, and vitamin C is a kind of water-soluble agent that delays senility, and delaying senility is ascorbic exemplary functions.In addition, vitamin C also has protective effect to vitamin E, and its reduction characteristic can make the stability of vitamin E strengthen, and the effect performance is more abundant, can strengthen their effect that delays senility when two kinds of vitamins are combined with, and plays synergy.
Along with Food Science man to its research deepen continuously and the consumer to the progressively raising of dietary fiber understanding, dietary fiber will equally become the indispensable nutritional labeling of human diet with other " six large nutrients ", be called as " the 7th nutrient ".The physicochemical property of dietary fiber mainly contains: stronger suction and expansion function; Can change microbiologic population's composition in the intestinal tract; Function with adsorb organic compound; Be combined and function of exchange with cation.These physicochemical characteristics of dietary fiber make it have unique physiological function and nutrition health-care functions.Be mainly manifested in the following aspects: the defaecation antiobesity action; Improve intestinal microenvironment; Regulate the blood sugar effect; Absorbing fats, cholesterol and cholate; Remove the harmful substance effect; Hypotensive action; Strengthen the health immunologic function.
The specific embodiment
Below in conjunction with embodiment the present invention is further described in detail:
Embodiment 1
Take by weighing the component of following weight portion: 40 parts in calcium carbonate, 19.3 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 8 parts of aminoglucose hydrochlorides, 4 parts of CPPs, 4 parts in natural VE powder, 4 parts of vitamin Cs, vitamin K
10.02 part in powder, Cobastab
120.00008 part, vitamin D
30.00009 part in powder, 8 parts of dietary fibers, 8 parts of microcrystalline celluloses, 3 parts of sodium carboxymethyl starches, 0.8 part of dolomol, 0.8 part of PVP K30,3 parts of stomach dissolved film coating pre-mix doses.
The preparation method: (1) takes by weighing component and the auxiliary material of above-mentioned weight portion, with described vitamin C, aminoglucose hydrochloride, vitamin K
1Powder, vitamin D
3Powder, Cobastab
12Pulverized respectively 100 mesh sieves, for subsequent use;
(2) add purified water in the described adhesive, be made into 8% the aqueous solution, for subsequent use.
(3) with described calcium compound, aminoglucose hydrochloride respectively in the trough type mixing machine, with the softwood processed respectively of the aqueous solution described in the step (2), crossing 20 mesh sieves with oscillating granulator granulates, in 60 ℃ of dryings, cross 20 mesh sieves with oscillating granulator again and carry out whole grain, make calcium compound particle and aminoglucose hydrochloride particle;
(4) with vitamin K
1Powder, Cobastab
12, vitamin D
3Powder and CPP shake at Highefficientpowersifter by the equivalent method of progressively increasing and sieve twice, and sieve number is 80 orders, and mixing makes mixture one;
(5) with described mixture one and vitamin C, natural VE powder at the Highefficientpowersifter sieve twice that shakes, mixing, sieve number is 40 orders, makes mixture two;
(6) prepared calcium compound particle, aminoglucose hydrochloride particle, the oligomeric Gly-His-Lys of Marine fishbone collagen, dietary fiber, diluent, disintegrant, lubricant and described mixture dual-purpose V-Mixer in the step (3) were always mixed 30 minutes, make the total mixture particle, its compressing tablet in tablet press machine is made label;
(7) described coating agent is dissolved in the ethanol, stir and add purified water after 10 minutes, strong stirring made coating solution in 45 minutes, the concentration of coating agent is 10%(W/W in the described coating solution), the concentration of ethanol is 70%, and label described in the step (6) is put into seed-coating machine, starts the seed-coating machine preheating that slowly runs, make the sheet surface temperature reach 35-40 ℃, open spray gun spray film, initial flow can be slightly large, observes at any time the label situation in the spray membrane process, in time adjust spray speed, the seed-coating machine rotating speed, notice that the sheet surface temperature can not be too high, cross wet, label weightening finish 3%, the heavy 1.0g of sheet, sprayed rear continuation and blown about 30 minutes with cool breeze, taken out to put into to dry in the air and dry about 2 hours between sheet.Dressing namely makes described health food.
Embodiment 2
Prescription: 50 parts of calcium citrates, 10 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 10 parts of aminoglucose hydrochlorides, 5.5 parts of CPPs, 5 parts in natural VE powder, 50 parts of vitamin Cs, vitamin K
10.03 part in powder, Cobastab
120.00009 part, vitamin D
30.0001 part in powder, 5 parts of dietary fibers, 4.6 parts of pregelatinized starch, 3 parts of sodium carboxymethyl starches, 0.8 part of dolomol, 1.0 parts of PVP K30s, 3 parts of stomach dissolved film coating pre-mix doses.
Preparation process (1)-(5) are with embodiment 1, to packing behind the whole grain of total mixture particle in the step (6) is made granule.
Embodiment 3
Prescription: 30 parts of Calcium Ascorbates, 30 parts in calcium chloride, 5 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 12 parts of aminoglucose hydrochlorides, 4 parts of CPPs, 6 parts in natural VE powder, 6 parts of vitamin Cs, vitamin K
10.04 part in powder, Cobastab
120.0001 part, vitamin D
30.00015 part in powder, 3.2 parts of dietary fibers, 2 parts in dextrin, 1 part in sweet mellow wine, 2.1 parts of Ac-Di-Sols, 0.3 part of superfine silica gel powder, 1.3 parts of PVP K30s, 3 parts of stomach dissolved film coating pre-mix doses.
Preparation process (1)-(5) are with embodiment 1, to packing behind the whole grain of total mixture particle in the step (6) is made granule.
Embodiment 4
Prescription: 70 parts of calcium gluconaes, 10 parts in calcium carbonate, 15 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 9 parts of aminoglucose hydrochlorides, 6 parts of CPPs, 7 parts in natural VE powder, 1 part of vitamin C, vitamin K
10.05 part in powder, Cobastab
120.00008 part, vitamin D
30.00009 part in powder, 20 parts of dietary fibers, 6.8 parts of lactose, 1 part of cross linked polyvinyl pyrrolidone, 1.0 parts of dolomols, 2 parts of Hydroxypropyl methylcelluloses, 3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Embodiment 5
Prescription: 40 parts in calcium carbonate, 10 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 30 parts of aminoglucose hydrochlorides, 10 parts of CPPs, 7.5 parts in natural VE powder, 8 parts of vitamin Cs, vitamin K
10.06 part in powder, Cobastab
120.00009 part, vitamin D
30.00015 part in powder, 15 parts of dietary fibers, 3.8 parts of microcrystalline celluloses, 3 parts of sodium carboxymethyl starches, 2 parts of talcum powder, 0.1 part of ethyl cellulose, 3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Embodiment 6
Prescription: 50 parts in calcium carbonate, 20 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 9 parts of aminoglucose hydrochlorides, 1 part of CPP, 4 parts in natural VE powder, 4 parts of vitamin Cs, vitamin K
10.08 part in powder, Cobastab
120.0005 part, vitamin D
30.0002 part in powder, 5.4 parts of dietary fibers, 1.5 parts of low-substituted hydroxypropyl celluloses, 0.5 part of lauryl sodium sulfate, 0.5 part of methylcellulose, 3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Embodiment 7
Prescription: 40 parts in calcium carbonate, 2 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 15 parts of aminoglucose hydrochlorides, 20 parts of CPPs, 0.25 part in natural VE powder, 4 parts of vitamin Cs, vitamin K
10.02 part in powder, Cobastab
120.0002 part, vitamin D
30.0001 part in powder, 10 parts of dietary fibers, 2.8 parts in dextrin, 3 parts of sodium carboxymethyl starches, 1.0 parts of dolomols, 0.1 part of PVP K30,3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Embodiment 8
Prescription: 60 parts in calcium carbonate, 7 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 11 parts of aminoglucose hydrochlorides, 4 parts of CPPs, 5 parts in natural VE powder, 15 parts of vitamin Cs, vitamin K
10.1 part in powder, Cobastab
120.00008 part, vitamin D
30.00012 part in powder, 2.5 parts of dietary fibers, 3 parts of sodium carboxymethyl starches, 1.0 parts of dolomols, 1.5 parts of PVP K30s, 3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Embodiment 9
Prescription: 40 parts in calcium carbonate, 10 parts of the oligomeric Gly-His-Lys of Marine fishbone collagen, 5 parts of aminoglucose hydrochlorides, 6 parts of CPPs, 10 parts in natural VE powder, 25 parts of vitamin Cs, vitamin K
10.02 part in powder, Cobastab
120.00008 part, vitamin D
30.00018 part in powder, 6 parts of dietary fibers, 6 parts in sweet mellow wine, 0.5 part of cross linked polyvinyl pyrrolidone, 0.5 part of dolomol, 1 part of hydroxypropyl cellulose, 3 parts of stomach dissolved film coating pre-mix doses.
The preparation method is with embodiment 1.
Can also save the granulation step in the step (2) among the preparation method of the present composition, make the powder of described composition.
The present invention can also make oral liquid according to conventional method.
Claims (7)
1. a composition that reduces bone-loss is characterized in that, it is made by the component of following weight portion:
Calcium compound 30-80 part, the oligomeric Gly-His-Lys 1-50 of Marine fishbone collagen part, aminoglucose hydrochloride 5-30 part, CPP 1-20 part, natural VE powder 0.25-7.5 part, vitamin C 1.5-50 part, vitamin K
1Powder 0.02-0.1 part, Cobastab
120.00005-0.0005 part, vitamin D
3Powder 0.000075-0.0005 part, dietary fiber 1-20 part;
Described Marine fishbone collagen oligopeptide choice for use molecular weight is less than the oligomeric Gly-His-Lys of 1000 daltonian Marine fishbone collagens.
2. composition according to claim 1, it is characterized in that described calcium compound is at least a in calcium carbonate, calcium citrate, calcium gluconae, calcium lactate, calcium malate, Calcium Ascorbate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, calcium acetate, calcium caseinate, calcium chloride, calcium citrate malate, calcium phosphate, calcium sulfate, calcium glycerophosphate or the amino acid chelated calcium.
3. composition according to claim 2 is characterized in that, the parts by weight of described each component are:
Calcium compound 40-60 part, the oligomeric Gly-His-Lys 5-20 of Marine fishbone collagen part, aminoglucose hydrochloride 8-20 part, CPP 4-10 part, natural VE powder 4-10 part, vitamin C 4-10 part, vitamin K
1Powder 0.02-0.05 part, Cobastab
120.00008-0.0001 part, vitamin D
3Powder 0.00009-0.0002 part, dietary fiber 2-8 part.
4. composition according to claim 3 is characterized in that, it also comprises the auxiliary material of following weight portion:
Diluent 0-40 part, disintegrant 0-10 part, lubricant 0.5-5 part, adhesive 0-5 part, coating agent 0-3 part.
5. health food according to claim 4 is characterized in that, the parts by weight of described auxiliary material are: diluent 4-10 part, disintegrant 1-5 part, lubricant 0.8-2 part, adhesive 0.5-3 part, coating agent 2-3 part.
6. composition according to claim 5 is characterized in that, described diluent is at least a in microcrystalline cellulose, pre-paying starch, lactose, dextrin, Icing Sugar or the sweet mellow wine; Described disintegrant is at least a in sodium carboxymethyl starch, cross linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose or the Ac-Di-Sol; Described lubricant is at least a in dolomol, superfine silica gel powder, lauryl sodium sulfate, talcum powder, hydrogenated vegetable oil, polyethylene glycols or the magnesium laurylsulfate; Described adhesive is at least a in distilled water, ethanol, starch slurry, sodium carboxymethylcellulose, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, Hydroxypropyl methylcellulose or the PVP K30; Described coating agent is stomach dissolved film coating pre-mix dose.
7. method for preparing such as claim 1,2,3,4,5 or 6 described compositions is characterized in that it carries out as follows:
A. take by weighing each component and auxiliary material by prescription, with described vitamin C, aminoglucose hydrochloride, vitamin K
1Powder, vitamin D
3Powder, Cobastab
12Sieve respectively, for subsequent use;
B. adhesive is made into the aqueous solution of mass concentration 8%, and is for subsequent use;
C. calcium compound, aminoglucose hydrochloride add the aqueous solution and make respectively softwood, granulate, and drying, whole grain makes calcium compound particle and aminoglucose hydrochloride particle;
D. with vitamin K
1Powder, Cobastab
12, vitamin D
3Powder and CPP shake at Highefficientpowersifter by the equivalent method of progressively increasing and sieve twice, and sieve number is 80 orders, and mixing makes mixture one;
E. described mixture one is shaken at Highefficientpowersifter with vitamin C, natural VE powder and sieve twice, mixing, sieve number is 40 orders, makes mixture two;
F. prepared calcium compound particle, aminoglucose hydrochloride particle, the oligomeric Gly-His-Lys of Marine fishbone collagen, dietary fiber, diluent, disintegrant, lubricant and described mixture dual-purpose mixer among the step c were always mixed 30 minutes, make the total mixture particle;
G. the total mixture particle that makes among the step f is directly packed the granulation agent or encapsulatedly made capsule or its compressing tablet in tablet press machine is made label, then, described coating agent is dissolved in the ethanol, stir and add purified water after 10 minutes, stir and made coating solution in 45 minutes, the concentration of coating agent is 10%(W/W in the described coating solution), the concentration of ethanol is 70%, and label described in the step f is put into the tablet that the seed-coating machine dressing namely makes health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110255107 CN102318835B (en) | 2011-08-31 | 2011-08-31 | Composition for reducing bone loss and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110255107 CN102318835B (en) | 2011-08-31 | 2011-08-31 | Composition for reducing bone loss and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102318835A CN102318835A (en) | 2012-01-18 |
| CN102318835B true CN102318835B (en) | 2013-01-09 |
Family
ID=45446779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110255107 Active CN102318835B (en) | 2011-08-31 | 2011-08-31 | Composition for reducing bone loss and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102318835B (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697802A (en) * | 2012-06-29 | 2012-10-03 | 广东仙乐制药有限公司 | A kind of calcium plus calcium preparation and preparation method thereof |
| CN102805858B (en) * | 2012-08-29 | 2014-04-23 | 山东省疾病预防控制中心 | High-efficiency calcium supplement capsule and preparation method thereof |
| CN103191414B (en) * | 2013-03-29 | 2014-10-22 | 武汉中博绿亚生物科技有限公司 | Fast-absorbed liquid calcium for pet and preparation method thereof |
| CN103478728B (en) * | 2013-08-29 | 2015-09-09 | 安徽珠峰生物科技有限公司 | A kind of compound calcium compensation powder and preparation method thereof |
| CN103520711A (en) * | 2013-10-24 | 2014-01-22 | 北京一品堂医药科技有限公司 | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition |
| CN103599525A (en) * | 2013-11-08 | 2014-02-26 | 苏州冉新生物技术有限公司 | Chelated calcium electuary |
| CN103736074B (en) * | 2013-11-21 | 2015-09-02 | 威海百合生物技术股份有限公司 | A kind of increase bone density health-caring capsule and preparation method thereof |
| CN103844273B (en) * | 2014-03-07 | 2015-05-20 | 禄美生物科技（上海）有限公司 | Collagen oral solution and preparation method thereof |
| AU2015257786B2 (en) * | 2014-05-05 | 2020-04-30 | Basf Se | Formulation of fat-soluble vitamin |
| CN104873950A (en) * | 2015-06-14 | 2015-09-02 | 威海紫光金奥力生物技术有限公司 | Fishbone glucosamine preparation for increasing bone mineral density and production method thereof |
| CN105288579A (en) * | 2015-11-14 | 2016-02-03 | 河北御芝林药业有限公司 | Calcium supplement agent and preparation method thereof |
| CN105410941A (en) * | 2015-12-08 | 2016-03-23 | 湖南洞庭水殖珍珠有限公司 | Serene Tablet health-care food capable of increasing bone density and strengthening immunity and preparation method thereof |
| CN105901688A (en) * | 2015-12-14 | 2016-08-31 | 威海百合生物技术股份有限公司 | Calcium-retaining health food and preparation method thereof |
| CN105581332A (en) * | 2015-12-31 | 2016-05-18 | 石家庄中硕药业有限公司 | Composition with skin moisture improving and antioxidation functions and preparation method |
| CN106213492A (en) * | 2016-07-22 | 2016-12-14 | 山东博奥克生物科技有限公司 | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density |
| CN107184960A (en) * | 2017-05-19 | 2017-09-22 | 江苏江大五棵松生物科技有限公司 | It is a kind of to be used to increase Bone gillg ammonia sugar-tablet of bone density and preparation method thereof |
| CN110338423A (en) * | 2018-04-08 | 2019-10-18 | 北京奥萨医药研究中心有限公司 | A kind of health food for the pre- preventing bone rarefaction of the middle-aged and the old |
| CN108740305B (en) * | 2018-05-10 | 2021-09-17 | 青岛农业大学 | Special calcium tablet for perinatal dairy cows and preparation method thereof |
| CN108783467B (en) * | 2018-06-04 | 2021-08-06 | 中食月太(北京)健康科技有限公司 | Composition for improving osteoporosis and increasing bone density and preparation method thereof |
| CN108785651A (en) * | 2018-07-06 | 2018-11-13 | 常同喜 | A kind of preparation method for the Bone gillg ammonia sugar-tablet increasing bone density |
| CN110651940A (en) * | 2019-10-26 | 2020-01-07 | 上海葡萄王企业有限公司 | Marine fishbone collagen oligopeptide powder solid beverage and preparation method thereof |
| CN110664994A (en) * | 2019-10-28 | 2020-01-10 | 珠海经济特区天然药物研究所有限公司 | Composition for treating osteoarticular diseases |
| CN111991360A (en) * | 2020-10-27 | 2020-11-27 | 中科院大连化学物理研究所张家港产业技术研究院有限公司 | Tremella polysaccharide oral tablet and preparation process thereof |
| CN116671638B (en) * | 2023-06-15 | 2024-03-22 | 江西维莱营健高科有限公司 | Casein calcium tablet and preparation method thereof |
| BE1031893B1 (en) * | 2024-02-23 | 2025-03-07 | Tosaka Int Co Ltd | GLUCOSAMINE PEPTIDE COMPOSITION AND ITS USE IN PROMOTING EXTENSIVE UTILIZATION OF CALCIUM |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101416734A (en) * | 2008-12-02 | 2009-04-29 | 河北金汉方生物科技开发有限公司 | Health-care products capable of improving skeleton and joint function and preparation method thereof |
| CN101537170A (en) * | 2008-03-17 | 2009-09-23 | 哈药集团制药六厂 | Compound for preventing osteoporosis and osteoarthrosis |
| CN101695382A (en) * | 2009-10-30 | 2010-04-21 | 洛阳新春都生物制药有限公司 | Calcium supplementing preparation with functions of improving bones and joints |
-
2011
- 2011-08-31 CN CN 201110255107 patent/CN102318835B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537170A (en) * | 2008-03-17 | 2009-09-23 | 哈药集团制药六厂 | Compound for preventing osteoporosis and osteoarthrosis |
| CN101416734A (en) * | 2008-12-02 | 2009-04-29 | 河北金汉方生物科技开发有限公司 | Health-care products capable of improving skeleton and joint function and preparation method thereof |
| CN101695382A (en) * | 2009-10-30 | 2010-04-21 | 洛阳新春都生物制药有限公司 | Calcium supplementing preparation with functions of improving bones and joints |
Non-Patent Citations (2)
| Title |
|---|
| 宋毅斐等.维生素从药品到保健食品的合理应用.《食品与药品》.2005,(第09期), * |
| 陶天遵等.维生素K与骨代谢.《国外医学.内分泌学分册》.2005,(第05期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102318835A (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102318835B (en) | Composition for reducing bone loss and preparation method thereof | |
| CN109207543A (en) | A kind of ox bone collagen protein peptides and preparation method and purposes | |
| CN106135890A (en) | A kind of alimentation composition contributing to bony articulation health | |
| CN105792837A (en) | Compositions comprising collagen peptides, elastin peptides and proteoglycans | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN102423487B (en) | Osteoarticular health-care composition and its application | |
| CN102894372A (en) | Health-care food for increasing bone density and preparation method thereof | |
| CN104982937B (en) | It is a kind of to promote sclerotin and the composition of periosteum for repairing and preparation method thereof | |
| CN101268835A (en) | Nutrition high calcium medicinal granule for children and preparing technique | |
| CN104939054A (en) | Health food capable of enhancing bone mineral density and immunity and preparation method of health food | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN110292175A (en) | Have effects that composition that hypoglycemic and fat reducing is shaped and its production method and application | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN109432388A (en) | The composition and its application in terms of bony articulation health of a kind of probiotics and aminoglucose hydrochloride | |
| CN105105143A (en) | Health-care food composition capable of increasing bone density, health-care food and preparation method | |
| CN109276710A (en) | A kind of composition for increasing bone density and preparation method and use thereof | |
| CN101401833B (en) | Composition for preventing and/or treating osteoporosis | |
| CN104824677A (en) | Bone density increase health food and preparation method thereof | |
| CN111569052A (en) | Composition for increasing bone mineral density of climacteric women and health product and application thereof | |
| CN115702687A (en) | Preparation and application of collagen peptide sodium hyaluronate amino acid composition | |
| CN118717952A (en) | Composition for increasing bone density and application thereof | |
| CN113729230A (en) | Composition for preventing osteoporosis or enhancing bone mineral density and preparation and application thereof | |
| CN108968075A (en) | It is a kind of improve bone health composition and its application | |
| CN110292177A (en) | A kind of composition and its preparation method and application promoting children's bone growth and development | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU TAINUO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHIJIAZHUANG ZHONGSHUO PHARMACEUTICAL GROUP Effective date: 20150116 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050021 SHIJIAZHUANG, HEBEI PROVINCE TO: 225300 TAIZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150116 Address after: 225300 science building, No. 1 drug city road, Jiangsu, Taizhou Patentee after: JIANGSU TAINUO MEDICINE CO., LTD. Address before: 050021 No. 58 Cang Feng Road, Yuhua District, Hebei, Shijiazhuang Patentee before: Shijiazhuang Zhongshuo Pharmaceutical Group Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170705 Address after: 225300 No. 816, drug city road, Jiangsu, Taizhou Patentee after: Shijiazhuang Pharmaceutical Group Pharmaceutical (Taizhou) Co., Ltd. CHINO Address before: 225300 science building, No. 1 drug city road, Jiangsu, Taizhou Patentee before: JIANGSU TAINUO MEDICINE CO., LTD. |
|
| TR01 | Transfer of patent right |